GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.

@article{Zarate2016GSK3AK,
  title={GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.},
  author={Carlos A. Zarate and roDriGo MaChaDo-vieira},
  journal={Bipolar disorders},
  year={2016},
  volume={18 8},
  pages={702-705}
}